McDermott Advises DBV on Its Capital Increase of 140.8 Million Euros


PARIS (March 29, 2018) –International law firm McDermott Will & Emery advised DBV Technologies (DBV) – a French clinical-stage biopharmaceutical company, on its capital increase by public offering in the United States, Canada and certain other countries outside Europe and by private placement in Europe (including in France).

DBV, listed on Euronext Paris and on the Nasdaq, raised 140.8 million euros following the exercise of the over-allotment option.

DBV is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy.

The McDermott team led by partners Emmanuelle Trombe and Bertrand Delafaye, included Aymeric Discours,Mathilde Peschard, Anaël Hadji, Stephan de Groër,Antoine Vergnat and Côme de Saint-Vincent.

About McDermott

McDermott Will & Emery is a premier international law firm with a diversified business practice. Numbering more than 1,000 lawyers, we have offices in Boston, Brussels, Chicago, Dallas, Düsseldorf, Frankfurt, Houston, London, Los Angeles, Miami, Milan, Munich, New York, Orange County, Paris, Seoul, Silicon Valley and Washington, DC. Further extending our reach into Asia, we have a strategic alliance with MWE China Law Offices in Shanghai.